Metabolic · Metabolic peptide (research)
HGH Fragment 176-191
- Drug class
- Metabolic peptide (research)
- Status
- Compounded (503A)
- Also known as
- frag 176-191, hgh frag, aod fragment, hgh 176-191
- Reviewed
- 2026-06-01 · Dr. Ana Lisa Carr, MD
What HGH Fragment 176-191 is studied for
- Targeted fat metabolism (research)
- No IGF-1 elevation (research)
- Non-insulinotropic (research)
Mechanism of action
HGH Fragment 176-191 is being studied in the metabolic category. GH fragment studied for fat metabolism without affecting blood sugar or IGF-1. Mechanism of action varies by study model; refer to the kindr clinical library for a deeper writeup.
Frequently asked questions
What is HGH Fragment 176-191?
HGH Fragment 176-191 is a metabolic peptide. GH fragment studied for fat metabolism without affecting blood sugar or IGF-1.
What is HGH Fragment 176-191 studied for?
Published research has examined HGH Fragment 176-191 for targeted fat metabolism, no igf-1 elevation, non-insulinotropic. Human clinical evidence varies by indication.
Is HGH Fragment 176-191 FDA-approved?
No. HGH Fragment 176-191 is not FDA-approved for the indications listed. It is available compounded by 503A pharmacies under clinician supervision, or for international research use only on this catalog.
How is HGH Fragment 176-191 used in research?
Protocols vary by study. HGH Fragment 176-191 is typically administered subcutaneously in research settings. No validated human therapeutic dose exists outside FDA-approved indications.
What are the known risks?
Long-term human safety data for HGH Fragment 176-191 is limited. Theoretical risks vary by mechanism. Any human use should be supervised by a licensed clinician.